215 related articles for article (PubMed ID: 17768034)
21. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia.
Morrissey I; Ge Y; Janes R
Int J Antimicrob Agents; 2009 Jun; 33(6):515-9. PubMed ID: 19203863
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of antibiotics to strains of periodontopathogenic bacteria within a single species biofilm - an in vitro study.
Eick S; Seltmann T; Pfister W
J Clin Periodontol; 2004 May; 31(5):376-83. PubMed ID: 15086620
[TBL] [Abstract][Full Text] [Related]
23. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST).
Bouchillon SK; Iredell JR; Barkham T; Lee K; Dowzicky MJ
Int J Antimicrob Agents; 2009 Feb; 33(2):130-6. PubMed ID: 18995992
[TBL] [Abstract][Full Text] [Related]
24. In vitro activity of mupirocin on clinical isolates of Staphylococcus aureus and its potential implications in chronic rhinosinusitis.
Ha KR; Psaltis AJ; Butcher AR; Wormald PJ; Tan LW
Laryngoscope; 2008 Mar; 118(3):535-40. PubMed ID: 18090864
[TBL] [Abstract][Full Text] [Related]
25. Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents.
Niederman MS; Anzueto A; Sethi S; Choudhri S; Kureishi A; Haverstock D; Perroncel R
Respir Med; 2006 Oct; 100(10):1781-90. PubMed ID: 16531032
[TBL] [Abstract][Full Text] [Related]
26. Cefdinir: an oral alternative to parenteral cephems.
Chatterjee A; Moland ES; Thomson KS
Diagn Microbiol Infect Dis; 2005 Apr; 51(4):259-64. PubMed ID: 15808317
[TBL] [Abstract][Full Text] [Related]
27. N-acetylcysteine inhibits growth, adhesion and biofilm formation of Gram-positive skin pathogens.
Eroshenko D; Polyudova T; Korobov V
Microb Pathog; 2017 Apr; 105():145-152. PubMed ID: 28237766
[TBL] [Abstract][Full Text] [Related]
28. In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens.
Jones RN; Bell JM; Sader HS; Turnidge JD; Stilwell MG
Diagn Microbiol Infect Dis; 2009 Apr; 63(4):434-9. PubMed ID: 19302927
[TBL] [Abstract][Full Text] [Related]
29. 10 years' experience with the pneumococcal quinolone moxifloxacin.
Burkhardt O; Welte T
Expert Rev Anti Infect Ther; 2009 Aug; 7(6):645-68. PubMed ID: 19681692
[TBL] [Abstract][Full Text] [Related]
30. In vitro comparison of combination and monotherapy for the empiric and optimal coverage of bacterial keratitis based on incidence of infection.
Kowalski RP; Kowalski TA; Shanks RM; Romanowski EG; Karenchak LM; Mah FS
Cornea; 2013 Jun; 32(6):830-4. PubMed ID: 23132444
[TBL] [Abstract][Full Text] [Related]
31. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance.
Jones RN; Kirby JT; Rhomberg PR
Diagn Microbiol Infect Dis; 2008 Jun; 61(2):203-13. PubMed ID: 18329835
[TBL] [Abstract][Full Text] [Related]
32. Influence of human ascitic fluid on the in vitro antibacterial activity of moxifloxacin.
Miglioli PA; Cappellari G; Cavallaro A; Cardaioli C; Sossai P; Fille M; Allerberger F
J Chemother; 2005 Aug; 17(4):401-3. PubMed ID: 16167519
[TBL] [Abstract][Full Text] [Related]
33. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
Schafer J; Hovde LB; Simonson D; Rotschafer JC
Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998
[TBL] [Abstract][Full Text] [Related]
34. [Resistance of causative agents of uncomplicated urinary tract infections in Russia].
Rafal'skiĭ VV; Strachunskiĭ LS; Babkin PA; Valenskaia VS; Gabbasova LA; Dmitrieva OB; Emel'ianova IV; Krupin VN; Malev IV; Petrov SB; Rokhlikov IM; Furletova NM; Khaĭrullov AS
Urologiia; 2006; (5):34-7. PubMed ID: 17444150
[TBL] [Abstract][Full Text] [Related]
35. In vitro interactions of LytA, the major pneumococcal autolysin, with two bacteriophage lytic enzymes (Cpl-1 and Pal), cefotaxime and moxifloxacin against antibiotic-susceptible and -resistant Streptococcus pneumoniae strains.
Rodríguez-Cerrato V; García P; Del Prado G; García E; Gracia M; Huelves L; Ponte C; López R; Soriano F
J Antimicrob Chemother; 2007 Nov; 60(5):1159-62. PubMed ID: 17827138
[TBL] [Abstract][Full Text] [Related]
36. Modulation of biofilm of strains isolated from patients with chronic obstructive pulmonary disease by levofloxacin, moxifloxacin, ciprofloxacin, amoxicillin/clavulanic acid and ceftriaxone.
Drago L; Mattina R; Legnani D; Romano CL; Vianello E; Ricci C; De Vecchi E
Int J Immunopathol Pharmacol; 2011; 24(4):1027-35. PubMed ID: 22230408
[TBL] [Abstract][Full Text] [Related]
37. Role of oral extended-spectrum cephems in the treatment of acute exacerbation of chronic bronchitis.
Anzueto A; Bishai WR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Mar; 57(3 Suppl):31S-38S. PubMed ID: 17349461
[TBL] [Abstract][Full Text] [Related]
38. Reversibility of antimicrobial resistance in respiratory isolates in HIV-positive Cambodian children after 36 months of HAART.
Shahum A; Benca G; Duong LS; Augustin A; Havlik S; Liska A; Kalavsky E; Beno P; Krcmery V
J Antimicrob Chemother; 2007 Jul; 60(1):194-7. PubMed ID: 17545143
[No Abstract] [Full Text] [Related]
39. In vitro study to compare sensitivity of amoxicillin+clavulanic acid and cefpodoxime+clavulanic acid among beta-lactamase positive clinical isolates of gram-positive and gram-negative pathogens.
Pal RB; Pal P; Jain S; Kulkarni KP
J Indian Med Assoc; 2008 Aug; 106(8):545-8. PubMed ID: 18975519
[TBL] [Abstract][Full Text] [Related]
40. Re: Acute bacterial prostatitis in Korea.
Etienne M; Caron F
Int J Antimicrob Agents; 2009 Aug; 34(2):185-6. PubMed ID: 19342203
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
